Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) rose 5.4% during trading on Tuesday . The stock traded as high as $16.77 and last traded at $16.50, with a volume of 175,346 shares. The stock had previously closed at $15.65.

ADMS has been the topic of several research analyst reports. JMP Securities initiated coverage on Adamas Pharmaceuticals in a research note on Friday, April 1st. They set an “outperform” rating and a $29.00 price objective on the stock. Noble Financial assumed coverage on Adamas Pharmaceuticals in a report on Friday, June 17th. They set a “buy” rating and a $25.00 target price for the company. Mizuho lowered their target price on Adamas Pharmaceuticals from $17.00 to $16.00 and set a “neutral” rating for the company in a report on Thursday, May 12th. Credit Suisse Group AG reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, June 22nd. Finally, Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $33.60.

The company’s market capitalization is $359.44 million. The firm’s 50-day moving average is $16.30 and its 200 day moving average is $16.98.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.11. On average, equities analysts expect that Adamas Pharmaceuticals Inc. will post ($3.09) earnings per share for the current fiscal year.

In related news, SVP Natalie Mcclure sold 36,000 shares of the business’s stock in a transaction on Monday, April 18th. The shares were sold at an average price of $18.50, for a total value of $666,000.00. Following the transaction, the senior vice president now owns 21,006 shares in the company, valued at $388,611. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Several large investors have bought and sold shares of the company. EAM Investors LLC acquired a new stake in Adamas Pharmaceuticals during the fourth quarter valued at approximately $4,006,000. Russell Frank Co increased its stake in shares of Adamas Pharmaceuticals by 119.8% in the fourth quarter. Russell Frank Co now owns 83,773 shares of the specialty pharmaceutical company’s stock worth $2,395,000 after buying an additional 45,652 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Adamas Pharmaceuticals by 585.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 69,411 shares of the specialty pharmaceutical company’s stock worth $1,966,000 after buying an additional 59,285 shares during the last quarter. Finally, Strs Ohio increased its stake in shares of Adamas Pharmaceuticals by 46.9% in the fourth quarter. Strs Ohio now owns 39,800 shares of the specialty pharmaceutical company’s stock worth $1,127,000 after buying an additional 12,700 shares during the last quarter.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.